Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387440983> ?p ?o ?g. }
- W4387440983 endingPage "792" @default.
- W4387440983 startingPage "781" @default.
- W4387440983 abstract "To explore the potential mechanism of resistance to axitinib in clear cell renal cell carcinoma (ccRCC), with a view to expanding the understanding of axitinib resistance, facilitating the design of more specific treatment options, and improving the treatment effectiveness and survival prognosis of patients.By exploring the half maximum inhibitory concentration (IC50) of axitinib on ccRCC cell lines 786-O and Caki-1, cell lines resistant to axitinib were constructed by repeatedly stimulated with axitinib at this concentration for 30 cycles in vitro. Cell lines that were not treated by axitinib were sensitive cell lines. The phenotypic differences of cell proliferation and apoptosis levels between drug resistant and sensitive lines were tested. Genes that might be involved in the drug resistance process were screened from the differentially expressed genes that were co-upregulated in the two drug resistant lines by transcriptome sequencing. The expression level of the target gene in the drug resistant lines was verified by real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB). The expression differences of the target gene in ccRCC tumor tissues and adjacent tissues were analyzed in the Gene Expression Profiling Interactive Analysis (GEPIA) public database, and the impact of the target gene on the prognosis of ccRCC patients was analyzed in the Kaplan-Meier Plotter (K-M Plotter) database. After knocking down the target gene in the drug resistant lines using RNA interference by lentivirus vector, the phenotypic differences of the cell lines were tested again. WB was used to detect the levels of apoptosis-related proteins in the different treated cell lines to find molecular pathways that might lead to drug resistance.Cell lines 786-O-R and Caki-1-R resistant to axitinib were successfully constructed in vitro, and their IC50 were significantly higher than those of the sensitive cell lines (10.99 μmol/L, P < 0.01; 11.96 μmol/L, P < 0.01, respectively). Cell counting kit-8 (CCK-8) assay, colony formation, and 5-ethynyl-2 '-deoxyuridine (EdU) assay showed that compared with the sensitive lines, the proliferative ability of the resistant lines decreased, but apoptosis staining showed a significant decrease in the level of cell apoptosis of the resistant lines (P < 0.01). Although resistant to axitinib, the resistant lines had no obvious new replicated cells in the environment of 20 μmol/L axitinib. Nuclear protein 1 (NUPR1) gene was screened by transcriptome sequencing, and its RNA (P < 0.0001) and protein expression levels significantly increased in the resistant lines. Database analysis showed that NUPR1 was significantly overexpressed in ccRCC tumor tissue (P < 0.05); the ccRCC patients with higher expression ofNUPR1had a worse survival prognosis (P < 0.001). Apoptosis staining results showed that knockdown ofNUPR1inhibited the anti-apoptotic ability of the resistant lines to axitinib (786-O, P < 0.01; Caki-1, P < 0.05). WB results showed that knocking downNUPR1decreased the protein level of B-cell lymphoma-2 (BCL2), increased the protein level of BCL2-associated X protein (BAX), decreased the protein level of pro-caspase3, and increased the level of cleaved-caspase3 in the resistant lines after being treated with axitinib.ccRCC cell lines reduce apoptosis through theNUPR1 -BAX/ BCL2 -caspase3 pathway, which is involved in the process of resistance to axitinib." @default.
- W4387440983 created "2023-10-10" @default.
- W4387440983 creator A5017646964 @default.
- W4387440983 creator A5018324670 @default.
- W4387440983 creator A5028838354 @default.
- W4387440983 creator A5039243289 @default.
- W4387440983 creator A5040169587 @default.
- W4387440983 creator A5061831125 @default.
- W4387440983 creator A5066241663 @default.
- W4387440983 creator A5071273509 @default.
- W4387440983 date "2023-10-18" @default.
- W4387440983 modified "2023-10-12" @default.
- W4387440983 title "[Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma]." @default.
- W4387440983 cites W1572996382 @default.
- W4387440983 cites W1989887854 @default.
- W4387440983 cites W1992532818 @default.
- W4387440983 cites W2012063336 @default.
- W4387440983 cites W2023952988 @default.
- W4387440983 cites W2054865582 @default.
- W4387440983 cites W2067216473 @default.
- W4387440983 cites W2130866079 @default.
- W4387440983 cites W2145220058 @default.
- W4387440983 cites W2162695817 @default.
- W4387440983 cites W2168427108 @default.
- W4387440983 cites W2209502000 @default.
- W4387440983 cites W2469624798 @default.
- W4387440983 cites W2732334708 @default.
- W4387440983 cites W2897704361 @default.
- W4387440983 cites W2908176514 @default.
- W4387440983 cites W2952697165 @default.
- W4387440983 cites W2961686530 @default.
- W4387440983 cites W2979711603 @default.
- W4387440983 cites W3018979351 @default.
- W4387440983 cites W3046152668 @default.
- W4387440983 cites W3093923068 @default.
- W4387440983 cites W3136595794 @default.
- W4387440983 cites W3165549650 @default.
- W4387440983 cites W3170291108 @default.
- W4387440983 cites W3216427242 @default.
- W4387440983 cites W4206109590 @default.
- W4387440983 cites W4229442376 @default.
- W4387440983 cites W4229452974 @default.
- W4387440983 cites W4315754639 @default.
- W4387440983 cites W4319057784 @default.
- W4387440983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37807730" @default.
- W4387440983 hasPublicationYear "2023" @default.
- W4387440983 type Work @default.
- W4387440983 citedByCount "0" @default.
- W4387440983 crossrefType "journal-article" @default.
- W4387440983 hasAuthorship W4387440983A5017646964 @default.
- W4387440983 hasAuthorship W4387440983A5018324670 @default.
- W4387440983 hasAuthorship W4387440983A5028838354 @default.
- W4387440983 hasAuthorship W4387440983A5039243289 @default.
- W4387440983 hasAuthorship W4387440983A5040169587 @default.
- W4387440983 hasAuthorship W4387440983A5061831125 @default.
- W4387440983 hasAuthorship W4387440983A5066241663 @default.
- W4387440983 hasAuthorship W4387440983A5071273509 @default.
- W4387440983 hasConcept C104317684 @default.
- W4387440983 hasConcept C143998085 @default.
- W4387440983 hasConcept C1491633281 @default.
- W4387440983 hasConcept C150194340 @default.
- W4387440983 hasConcept C153911025 @default.
- W4387440983 hasConcept C162317418 @default.
- W4387440983 hasConcept C190283241 @default.
- W4387440983 hasConcept C2776539811 @default.
- W4387440983 hasConcept C2777472916 @default.
- W4387440983 hasConcept C2778019345 @default.
- W4387440983 hasConcept C2778695046 @default.
- W4387440983 hasConcept C2781278892 @default.
- W4387440983 hasConcept C502942594 @default.
- W4387440983 hasConcept C54355233 @default.
- W4387440983 hasConcept C62112901 @default.
- W4387440983 hasConcept C71924100 @default.
- W4387440983 hasConcept C81885089 @default.
- W4387440983 hasConcept C86803240 @default.
- W4387440983 hasConceptScore W4387440983C104317684 @default.
- W4387440983 hasConceptScore W4387440983C143998085 @default.
- W4387440983 hasConceptScore W4387440983C1491633281 @default.
- W4387440983 hasConceptScore W4387440983C150194340 @default.
- W4387440983 hasConceptScore W4387440983C153911025 @default.
- W4387440983 hasConceptScore W4387440983C162317418 @default.
- W4387440983 hasConceptScore W4387440983C190283241 @default.
- W4387440983 hasConceptScore W4387440983C2776539811 @default.
- W4387440983 hasConceptScore W4387440983C2777472916 @default.
- W4387440983 hasConceptScore W4387440983C2778019345 @default.
- W4387440983 hasConceptScore W4387440983C2778695046 @default.
- W4387440983 hasConceptScore W4387440983C2781278892 @default.
- W4387440983 hasConceptScore W4387440983C502942594 @default.
- W4387440983 hasConceptScore W4387440983C54355233 @default.
- W4387440983 hasConceptScore W4387440983C62112901 @default.
- W4387440983 hasConceptScore W4387440983C71924100 @default.
- W4387440983 hasConceptScore W4387440983C81885089 @default.
- W4387440983 hasConceptScore W4387440983C86803240 @default.
- W4387440983 hasIssue "5" @default.
- W4387440983 hasLocation W43874409831 @default.
- W4387440983 hasOpenAccess W4387440983 @default.
- W4387440983 hasPrimaryLocation W43874409831 @default.
- W4387440983 hasRelatedWork W1985998670 @default.